US FDA finalizes three biosimilars guidances
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration can knock three biosimilars guidances off its to-do list after finalizing the documents and giving industry more certainty on what's needed to submit so-called 351(k) applications to the agency and gain approval.